KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Amortizatization of Intangibles (2016 - 2025)

Abbott Laboratories' Amortizatization of Intangibles history spans 17 years, with the latest figure at $422.0 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 9.25% year-over-year to $422.0 million; the TTM value through Dec 2025 reached $1.7 billion, down 10.44%, while the annual FY2025 figure was $1.7 billion, 10.44% down from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $422.0 million at Abbott Laboratories, roughly flat from $420.0 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $520.0 million in Q3 2021 and bottomed at $420.0 million in Q1 2025.
  • The 5-year median for Amortizatization of Intangibles is $493.5 million (2022), against an average of $479.3 million.
  • The largest annual shift saw Amortizatization of Intangibles grew 1.96% in 2021 before it decreased 11.02% in 2025.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $514.0 million in 2021, then decreased by 3.5% to $496.0 million in 2022, then dropped by 3.02% to $481.0 million in 2023, then decreased by 3.33% to $465.0 million in 2024, then decreased by 9.25% to $422.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Amortizatization of Intangibles are $422.0 million (Q4 2025), $420.0 million (Q3 2025), and $420.0 million (Q2 2025).